and by biogen idec. úú@@ppúú@@úú

look to biogen idec, which should have a breakout 2012. i'd like it even more on a market inspired pullback. let's go to richard in virginia. richard. >> caller: jim, what's the word on dfr? rj invested 10 million in this company and i'm reading they're posed to be the next blockbuster in the world of cancer. >> i got work to do on that. i don't get these questions ahead of time. i'm completely stumped by richard in virginia and i'd rather say i'm stumped. so i got to come back. let's go to jeannine in new york. >> caller: hi, jim. a great big hello from the north country of new york. >> must be snowy up there. >> caller: a little bit. got some left. i'm watching idenix, novartis purchased some stock. is this a good buy and possibly a small biopharma company positioned for a takeover? >> i don't want to recommend that -- i understand why you want to say it could be a takeover. i think you should own it because i think it going to do well on its own. i don't know if it's going to get taken over. it may not have to be. i do like hep c and i